Bioventix (LON:BVXP) had its target price increased by research analysts at FinnCap from GBX 3,400 ($44.43) to GBX 3,700 ($48.35) in a report issued on Friday, March 29th, ThisIsMoney.Co.Uk reports. The brokerage presently has a “corporate” rating on the biotechnology company’s stock. FinnCap’s price target suggests a potential downside of 3.90% from the company’s current price.
BVXP stock traded down GBX 100 ($1.31) during midday trading on Friday, reaching GBX 3,850 ($50.31). The company’s stock had a trading volume of 3,471 shares, compared to its average volume of 5,505. The stock has a market cap of $199.75 million and a PE ratio of 36.05. Bioventix has a 52 week low of GBX 2,510 ($32.80) and a 52 week high of GBX 4,060 ($53.05).
Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications.
Read More: Trading Options- What is a Strangle?
Receive News & Ratings for Bioventix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bioventix and related companies with MarketBeat.com’s FREE daily email newsletter.